文献速递产科母胎医学

围产期情绪与焦虑障碍:利用血浆蛋白质组学发现生物标志物

Perinatal mood and anxiety disorders: biomarker discovery using plasma proteomics.
PubMed 文献 · Am J Obstet Gynecol · 2023-01-14

本研究纳入52名孕妇(34名有围产期情绪与焦虑障碍风险,18名对照),在孕晚期和产后3个月进行心理健康筛查,用SomaLogic SomaScan检测孕晚期血浆1305种蛋白质。围产期情绪与焦虑障碍组有独特的血浆蛋白特征,涉及神经元信号和促炎通路;需更大样本验证。

要点

  • 孕晚期血浆蛋白质组学可区分有围产期情绪与焦虑障碍风险的孕妇与对照。
  • 20种蛋白质特征在主成分分析中区分围产期情绪与焦虑障碍组与对照(P<.05)。
  • 无子痫前期的围产期情绪与焦虑障碍组有30种蛋白质特征(P<.001)。

核心结论

  • 围产期情绪与焦虑障碍患者具有独特的血浆蛋白特征,调控多种神经元信号和促炎通路。
  • 需要更大样本的验证研究来确定这些分子是否可与传统风险因素联合用于围产期情绪与焦虑障碍的早期检测。

研究设计与样本

  • 研究纳入52名女性,其中34名有围产期情绪与焦虑障碍风险,18名为对照。
  • 在孕晚期和产后3个月两个时间点进行心理健康筛查。
  • 孕晚期血浆样本使用基于适配体的SomaLogic SomaScan蛋白质组学检测技术筛查1305种蛋白质分析物。

主要发现

  • 从53种显著的围产期情绪与焦虑障碍相关蛋白质中,一个独特的20种蛋白质特征在主成分分析中区分围产期情绪与焦虑障碍病例与对照(P<.05)。
  • 该蛋白质特征包括NCAM1、NRCAM和NTRK3,汇聚于调节轴突导向、星形胶质细胞分化和GABA能神经元维持的神经元信号通路。
  • 当分析限制于无子痫前期的受试者时,一个30种蛋白质特征在主成分分析中区分围产期情绪与焦虑障碍病例与所有对照,无重叠(P<.001)。
  • 在无子痫前期的围产期情绪与焦虑障碍组中,观察到CXCL11、CXCL6、MIC-B和B2MG等调节白细胞迁移、炎症和免疫功能的蛋白质表达增加。

关键数值与推荐

  • 围产期情绪与焦虑障碍风险通过两个时间点筛查确定:抑郁(爱丁堡产后抑郁量表≥12)、焦虑(总体焦虑严重程度与损害量表≥7)和/或创伤后应激障碍(事件影响量表>26)高于验证界值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大样本的额外验证研究来确定这些分子是否可与传统风险因素联合用于围产期情绪与焦虑障碍的早期检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perinatal mood and anxiety disorders encompass a range of mental health disorders that occur during pregnancy and up to 1 year postpartum, affecting approximately 20% of women. Traditional risk factors, such as a history of depression and pregnancy complications including preeclampsia, are known. Their predictive utility, however, is not specific or sensitive enough to inform clinical decision-making or prevention strategies for perinatal mood and anxiety disorders. Better diagnostic and prognostic models are needed for early identification and referral to treatment. OBJECTIVE: This study aimed to determine if a panel of novel third-trimester plasma protein biomarkers in pregnant women can be used to identify those who have a high predisposed risk for perinatal mood and anxiety disorders within 3 months postpartum. STUDY DESIGN: We studied 52 women (n=34 with a risk for perinatal mood and anxiety disorders and n=18 controls) among whom mental health screening was conducted at 2 time points, namely in the third trimester and again at 3 months postdelivery. An elevated perinatal mood and anxiety disorder risk was identified by screening individuals with above-validated cutoffs for depression (Edinburgh Postnatal Depression Scale ≥12), anxiety (Overall Anxiety Severity and Impairment Scale ≥7), and/or posttraumatic stress disorder (Impact of Events Scale >26) at both time points. Plasma samples collected in the third trimester were screened using the aptamer-based SomaLogic SomaScan proteomic assay technology to evaluate perinatal mood and anxiety disorder-associated changes in the expression of 1305 protein analytes. Ingenuity Pathway Analysis was conducted to highlight pathophysiological relationships between perinatal mood and anxiety disorder-specific proteins found to be significantly up- or down-regulated in all subjects with perinatal mood and anxiety disorder and in those with perinatal mood and anxiety disorders and no preeclampsia. RESULTS: From a panel of 53 significant perinatal mood and anxiety disorder-associated proteins, a unique 20-protein signature differentiated perinatal mood and anxiety disorder cases from controls in a principal component analysis (P<.05). This protein signature included NCAM1, NRCAM, and NTRK3 that converge around neuronal signaling pathways regulating axonal guidance, astrocyte differentiation, and maintenance of GABAergic neurons. Interestingly, when we restricted the analysis to subjects without preeclampsia, a 30-protein signature differentiated perinatal mood and anxiety disorder cases from all controls without overlap on the principal component analysis (P<.001). In the nonpreeclamptic perinatal mood and anxiety disorder group, we observed increased expression of proteins, such as CXCL11, CXCL6, MIC-B, and B2MG, which regulate leucocyte migration, inflammation, and immune function. CONCLUSION: Participants with perinatal mood and anxiety disorders had a unique and distinct plasma protein signature that regulated a variety of neuronal signaling and proinflammatory pathways. Additional validation studies with larger sample sizes are needed to determine whether some of these molecules can be used in conjunction with traditional risk factors for the early detection of perinatal mood and anxiety disorders.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Accortt E, Mirocha J, Zhang D, et al. Perinatal mood and anxiety disorders: biomarker discovery using plasma proteomics. Am J Obstet Gynecol. 2023. PMID: 36649818. doi:10.1016/j.ajog.2023.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。